According to the American Society of Clinical Oncology (ASCO) guidelines and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), this assay can also help physicians decide if extending hormonal therapy in patients with HR+/HER2−, LN-negative or LN-positive (1–3 nodes) BC beyond five years (for a total of 10 years) would be beneficial [31]. The gene discussed is HR; the disease is breast cancer.